Download PDF

1. Company Snapshot

1.a. Company Description

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers.


In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma.Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC.Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates.


It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited.The company was incorporated in 2014 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on PSTX

Poseida Therapeutics' recent performance was negatively driven by the impending acquisition by Roche, which was completed on January 8, 2025 for $1.5 billion. This acquisition resulted in Poseida's shareholders receiving $23.03 per share, effectively ending the company's independence. The transaction's completion likely led to a loss of control and decision-making power for Poseida's management team, potentially impacting future growth and strategic direction.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

Jul -23

Source: globenewswire.com

Card image cap

Roche set to finalise $1.5bn Poseida Therapeutics takeover

Jan -08

Source: proactiveinvestors.com

Card image cap

Roche to complete acquisition of U.S. biopharma company Poseida

Jan -08

Source: reuters.com

Card image cap

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

Dec -09

Source: prnewswire.com

Card image cap

Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?

Nov -28

Source: zacks.com

Card image cap

POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX

Nov -27

Source: businesswire.com

Card image cap

Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet

Nov -27

Source: zacks.com

Card image cap

Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?

Nov -27

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.05%)

6. Segments

Cell and Gene Therapies

Expected Growth: 14.05%

Poseida Therapeutics' Cell and Gene Therapies segment growth is driven by increasing adoption of CAR-T cell therapies, strong pipeline of gene editing programs, and partnerships with leading pharmaceutical companies. Additionally, growing demand for targeted cancer treatments, advancements in gene editing technologies, and expanding indications for existing products contribute to the 14.05% growth.

7. Detailed Products

BCMA Targeted CAR-T Cell Therapy

Autologous CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma

PSMA Targeted CAR-T Cell Therapy

Allogenic CAR-T cell therapy targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer

PSCA Targeted CAR-T Cell Therapy

Autologous CAR-T cell therapy targeting prostate stem cell antigen (PSCA) for the treatment of pancreatic cancer

BCMA Allogenic CAR-T Cell Therapy

Allogenic CAR-T cell therapy targeting BCMA for the treatment of relapsed/refractory multiple myeloma

P-PSMA-101 (PSMA-Targeted Autologous CAR-T Cell Therapy)

Autologous CAR-T cell therapy targeting PSMA for the treatment of metastatic castration-resistant prostate cancer

8. Poseida Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Poseida Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative gene therapies and treatments for similar diseases.

Bargaining Power Of Customers

Poseida Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for innovative gene therapies.

Bargaining Power Of Suppliers

Poseida Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment, but also due to the specialized nature of some of the components required for gene therapy production.

Threat Of New Entrants

Poseida Therapeutics, Inc. faces a high threat of new entrants due to the growing interest in gene therapy and the increasing number of biotech startups and pharmaceutical companies investing in gene therapy research and development.

Intensity Of Rivalry

Poseida Therapeutics, Inc. operates in a highly competitive industry with several established players and a growing number of new entrants, leading to a high intensity of rivalry in the gene therapy market.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 38.36%
Debt Cost 3.95%
Equity Weight 61.64%
Equity Cost 6.22%
WACC 5.35%
Leverage 62.24%

11. Quality Control: Poseida Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Arbutus Biopharma

A-Score: 4.4/10

Value: 6.0

Growth: 4.0

Quality: 3.9

Yield: 0.0

Momentum: 7.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
BioCryst Pharmaceuticals

A-Score: 4.4/10

Value: 5.0

Growth: 7.2

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Ocular Therapeutix

A-Score: 4.0/10

Value: 6.2

Growth: 5.0

Quality: 4.3

Yield: 0.0

Momentum: 6.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Poseida Therapeutics

A-Score: 3.8/10

Value: 4.2

Growth: 4.6

Quality: 4.1

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
EyePoint Pharmaceuticals

A-Score: 3.7/10

Value: 6.6

Growth: 2.3

Quality: 4.9

Yield: 0.0

Momentum: 7.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
G1 Therapeutics

A-Score: 3.7/10

Value: 6.0

Growth: 6.4

Quality: 4.2

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.5$

Current Price

9.5$

Potential

-0.00%

Expected Cash-Flows